William P. Kane Jr - Aug 16, 2021 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Role
Chief Commercial Officer
Signature
/s/ Richard I. Steinhart, as Attorney-in-Fact
Stock symbol
BTAI
Transactions as of
Aug 16, 2021
Transactions value $
$0
Form type
4
Date filed
8/18/2021, 05:25 PM
Next filing
Feb 7, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BTAI Stock Option (Right to Buy) Award $0 +40K $0.00 40K Aug 16, 2021 Common Stock 40K $23.84 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of August 16, 2021 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person'scontinuous employment with the Issuer through the relevant vesting dates.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney